Drug Safety Settlement
Japanese drugmaker Daiichi Sankyo Co, which bought control of Ranbaxy Laboratories in 2008, said it believes unnamed former shareholders of the company hid information regarding U.S. regulatory probes into Ranbaxy. Full Article
- Gold slips after Bernanke hints at slowing bond buys
- FBI says man shot dead while being questioned about Boston bombings
- British soldier hacked to death in suspected Islamist attack
- Soldier hacked to death in London in suspected Islamist attack
- Short story writer Lydia Davis wins Man Booker International fiction prize
Confused while buying stocks? Get buy, sell or hold recommendations from VantageTrade. Full Coverage
Bharti Airtel gains on tariff hike hopes
Reuters Market Eye - Shares in Bharti Airtel(BRTI.NS) rise 2.3 percent, heading for their fifth consecutive session of gains, as more brokerages upgrade the stock after last week's auction of 2G spectrum fetched lower prices than the government had targeted.
Bharti shares surged 9.3 percent last week, the biggest weekly gain since late September.
Credit Suisse upgraded Bharti to 'outperform' from 'underperform', and raised its target price to 355 rupees from 225 rupees, citing greater clarity on the regulatory front and reduced competitiveness in the domestic sector.
The investment banks add operators could also be testing markets for tariff hikes by reducing discounts.
"While the recent rally in stocks has been led by easing regulatory concerns, we believe the next leg will be driven by tariff increases," Credit Suisse said in a note dated on Monday.
Goldman Sachs upgraded the stock as well, to 'buy' from 'neutral', also citing reduced regulatory risk and potential for tariff hikes, according to a note dated on Friday.
"We see room for potential tariff hikes in coming months as operators focus on reducing losses and pass the burden of higher spectrum on to consumers," Goldman wrote.
- Tweet this
- Share this
- Digg this